David Benhayon
Child & Adolescent Psychiatry · Indiana, PANPI 1083824130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,628 and has fallen 63.2% since, to $599 in 2025. Among child & adolescent psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$495
- Neurocrine Biosciences, Inc.$381
- AbbVie$294
- Lundbeck LLC$291
- Novartis$252
- plus $3K from 36 others
What the payments were for
- Food & beverage$5,42899%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,456 in reported general payments places this provider in the 90th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate ErMethylphenidate Hcl | 24 | $2,131 |
| Bupropion Hcl | 29 | $1,346 |
| Fluvoxamine Maleate | 24 | $595 |
| Divalproex Sodium ErDivalproex Sodium | 37 | $456 |
| Sertraline Hcl | 22 | $437 |
| Prazosin Hcl | 34 | $401 |
| Guanfacine Hcl ErGuanfacine Hcl | 29 | $383 |
| Buspirone Hcl | 28 | $372 |
| Doxepin Hcl | 11 | $361 |
| Clonazepam | 27 | $322 |
| Duloxetine Hcl | 16 | $305 |
| Aripiprazole | 23 | $283 |
| Benztropine Mesylate | 22 | $236 |
| Lamotrigine | 17 | $225 |
| Mirtazapine | 24 | $218 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Indiana
- Dennis BorczonErie$120K
- Suzanne LucotCranberry Township$72K
- Dan UdreaWexford$51K
- Robert WilsonErie$34K
- Craig FeasterState College$18K
- Thomas WindPhiladelphia$17K
- Laura AdangPhiladelphia$15K
- Christoph LamPhiladelphia$13K
- Raman BawejaHershey$11K
- Jeffrey HermannYork$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.